ABSTRACT
Clinical research in the United States on the wake-promoting agent modafinil began in 1993, when Cephalon, Inc., a Pennsylvania-based biotechnology firm, licensed the rights to modafinil in the U.S. from its developer, French pharmaceutical company Laboratorie L. Lafon (1). Modafinil was approved for use in narcolepsy in France in 1992, and had been studied in other disorders of excessive sleepiness in that country, as well as for depression and “vigilance enhancement” (1,2).
